C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025
상품코드:1704072
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 200 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 9.3%의 성장률로 25억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 HIV 및 AIDS에서의 용도 확대, 줄기세포 동원에 대한 수요 증가, 자가면역질환에서의 잠재력, 바이오뱅크 개념의 성장, 신약개발에 인공지능(AI)의 통합 등에 기인할 것으로 보입니다. 예측 기간 중 주요 동향으로는 희귀질환 치료제 개발에 대한 관심 증가, 병용요법 개발, 정밀 종양학 접근법 채택, 신규 치료제 임상시험 확대, 약물전달 기술 발전 등을 꼽을 수 있습니다.
HIV는 CD4(T) 세포를 공격하여 면역 체계를 표적으로 삼고 약화시키는 바이러스로, 치료하지 않으면 AIDS로 이어질 수 있으며, HIV 유병률이 증가함에 따라 경련성 발성 장애 치료 시장의 성장을 가속할 것으로 예상됩니다. CXCR4 길항제는 CXCR4 수용체를 억제하여 바이러스가 면역세포에 접근하여 감염되는 것을 막음으로써 HIV를 억제하고, HIV가 면역세포에 접근하여 감염되는 것을 방지합니다. 방지합니다. 예를 들어 유엔에이즈계획(UNAIDS)에 따르면 2022년에는 전 세계 3,900만 명(3,310만-4,570만 명)의 HIV 감염자가 있으며, 그 해 신규 감염자는 130만 명(100만-170만 명)에 달할 것으로 예상됩니다. 결과적으로 HIV 유병률 증가는 CXCR4 길항제 시장 확대에 박차를 가하고 있습니다.
CXCR4 길항제 시장의 주요 기업은 다양한 질환의 치료 옵션과 환자 예후를 개선하기 위해 생물학적 동등물 개발에 주력하고 있습니다. 생물학적 동등물이란 유사한 조건에서 비교했을 때 유사한 생체 이용률을 가진 의약품을 말합니다. 예를 들어 2024년 5월 인도의 제네릭 주사제 제조업체인 글랜드 파마(Gland Pharma)는 미국 식품의약국(FDA)으로부터 프레릭사포(Prelixafor) 주사제를 승인받았습니다. 이 제품은 젠자임 코퍼레이션의 오리지널 의약품인 MOZOBIL(프레릭사포르) 주사제와 생물학적으로 동등하며, 치료적 측면에서도 동등합니다. 프레릭사홀은 CXCR4 길항제로 비호지킨림프종 및 다발성골수종 환자에서 조혈모세포를 말초혈액으로 동원하여 채취 및 자가이식을 위해 과립구 콜로니 자극인자와 병용투여합니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 C-X-C 케모카인 수용체 4(CXCR4) 길항제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 성장률 분석
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 실적 : 규모와 성장, 2019-2024
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 C-X-C 케모카인 수용체 4(CXCR4) 길항제 TAM(Total Addressable Market)
제6장 시장 세분화
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
BL-8040
GMI-1359
Plerixafor(AMD3100)
Balixafortide(POL6326)
USL311
Burixafor(GPC-100)
기타 유형
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
주사제
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 제품 파이프라인별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
승인
임상시험
전임상
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
암
인간면역결핍바이러스(HIV)
만성 염증 질환
줄기세포 동원
면역 질환과 자가면역질환
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, BL-8040의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
종양학에 대한 응용(백혈병, 림프종)
줄기세포 동원
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, GMI-1359의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
암치료(유방암, 고형 종양)
골수 이식
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, Plerixafor(AMD3100)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
조혈모세포 동원
암치료(다발성골수종)
HIV 치료(HIV 리저버)
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, Balixafortide(POL6326)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
암치료(고형 종양, 유방암)
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, USL311의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
줄기세포 동원
종양학 애플리케이션
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, Burixafor(GPC-100)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
암치료(림프종, 고형 종양)
줄기세포 동원
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장, 기타 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
실험적 또는 전임상적 CXCR4 길항제
CXCR4 길항제와의 병용요법
제7장 지역별·국가별 분석
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 경쟁 구도
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Sanofi Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
GlaxoSmithKline
Eli Lilly and Company
Amgen Inc.
Takeda Chemical Industries Ltd.
Kyowa Kirin Co. Ltd.
BioLegend Inc.
Kura Oncology Inc.
CUSABIO TECHNOLOGY LLC
Cayman Chemical
X4 Pharmaceuticals Inc.
BioLineRx Ltd.
Spexis Ltd.
Biokine Therapeutics Ltd.
GlycoMimetics
AnorMED Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 2029 : 새로운 기회를 제공하는 국가
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 2029 : 새로운 기회를 제공하는 부문
C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁의 전략
제36장 부록
KSA
영문 목차
영문목차
C-X-C chemokine receptor 4 (CXCR4) antagonists are pharmaceutical compounds aimed at inhibiting the CXCR4 receptor, which is found on the surface of specific cells. These antagonists function by blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as SDF-1), a key player in cell migration, hematopoiesis, and immune responses.
The main types of CXCR4 antagonists include BL-8040, GMI-1359, plerixafor (AMD3100), balixafortide (POL6326), USL311, burixafor (GPC-100), and others. These antagonists can be administered orally or via injection. BL-8040, for example, is a synthetic peptide developed to block CXCR4, which is involved in cancer cell migration and survival. The product pipelines feature both approved clinical trials and pre-clinical trials for a range of applications, including cancer, human immunodeficiency virus (HIV), chronic inflammatory diseases, stem cell mobilization, and immune and autoimmune diseases. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The C-X-C chemokine receptor 4 (CXCR4) antagonist market research report is one of a series of new reports from The Business Research Company that provides C-X-C chemokine receptor 4 (CXCR4) antagonist market statistics, including C-X-C chemokine receptor 4 (CXCR4) antagonist industry global market size, regional shares, competitors with a C-X-C chemokine receptor 4 (CXCR4) antagonist market share, detailed C-X-C chemokine receptor 4 (CXCR4) antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor 4 (CXCR4) antagonist industry. This C-X-C chemokine receptor 4 (CXCR4) antagonist market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The C-X-C chemokine receptor 4 (CXCR4) antagonists market size has grown strongly in recent years. It will grow from $1.62 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing transparency in clinical trial data, patient-centric healthcare policies, rising prevalence of chemotherapy resistance, policies emphasizing patient-centered care and access, and increasing preference for targeted therapies.
The C-X-C chemokine receptor 4 (CXCR4) antagonists market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.
The rise in human immunodeficiency virus (HIV) prevalence is expected to drive growth in the spasmodic dysphonia treatment market. HIV, a virus that targets and weakens the immune system by attacking CD4 (T) cells, can lead to AIDS if untreated. The increasing prevalence of HIV is due to factors such as low awareness, limited healthcare access, high transmission rates, and inadequate prevention in some regions. CXCR4 antagonists help manage HIV by blocking the CXCR4 receptor, preventing the virus from accessing and infecting immune cells, thus aiding in controlling the virus and enhancing immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] people living with HIV globally, with 1.3 million [1 million-1.7 million] new infections that year. Consequently, the growing prevalence of HIV is fueling the expansion of the CXCR4 antagonist market.
Leading companies in the CXCR4 antagonist market are focusing on developing bioequivalents to improve treatment options and patient outcomes for various diseases. Bioequivalents are pharmaceutical products that have similar bioavailability when compared under similar conditions. For example, in May 2024, Gland Pharma, an India-based generic injectable manufacturer, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. This product is bioequivalent and therapeutically equivalent to the reference drug, MOZOBIL (plerixafor) injection by Genzyme Corporation. Plerixafor is a CXCR4 antagonist used in conjunction with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
In April 2024, PANTHERx, a US-based specialty pharmacy, partnered with X4 Pharmaceuticals Inc. to facilitate the distribution of XOLREMDI (mavorixafor). This oral treatment, taken once daily, selectively antagonizes the CXCR4 receptor and was approved by the U.S. Food and Drug Administration (FDA). It is the first FDA-approved therapy specifically indicated for patients aged 12 and older with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. X4 Pharmaceuticals Inc., a US-based late-stage clinical biopharmaceutical company, focuses on developing and commercializing novel therapeutics, including CXCR4 antagonists such as XOLREMDI (mavorixafor).
Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.
North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2024. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The C-X-C chemokine receptor 4 (CXCR4) antagonist market consists of sales of TN14003 (Trogarzo), X4P-001 (Mavorixafor), TG-0054, and KRH-3955. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on c-x-c chemokine receptor 4 (cxcr4) antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for c-x-c chemokine receptor 4 (cxcr4) antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The c-x-c chemokine receptor 4 (cxcr4) antagonists market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: BL-8040; GMI-1359; Plerixafor (AMD3100); Balixafortide (POL6326); USL311; Burixafor (GPC-100); Other Types
2) By Route Of Administration: Oral; Injectable
3) By Product Pipeline: Approved; Clinical Trials; Pre-Clinical
4) By Application: Cancer; Human Immunodeficiency Virus (HIV); Chronic Inflammatory Disease; Stem Cell Mobilization; Immune And Autoimmune Diseases
5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By BL-8040: Oncology Applications (Leukemia, Lymphoma); Stem Cell Mobilization
2) By GMI-1359: Cancer Treatment (Breast Cancer, Solid Tumors); Bone Marrow Mobilization
3) By Plerixafor (AMD3100): Hematopoietic Stem Cell Mobilization; Cancer Treatment (Multiple Myeloma); HIV Treatment (HIV Reservoirs)
4) By Balixafortide (POL6326): Cancer Treatment (Solid Tumors, Breast Cancer)
5) By USL311: Stem Cell Mobilization; Oncology Applications
6) By Burixafor (GPC-100): Cancer Treatment (Lymphoma, Solid Tumors); Stem Cell Mobilization
7) By Other Types: Experimental Or Preclinical CXCR4 Antagonists; Combination Therapies With CXCR4 Antagonists
4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Growth Analysis And Strategic Analysis Framework
5.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BL-8040
GMI-1359
Plerixafor (AMD3100)
Balixafortide (POL6326)
USL311
Burixafor (GPC-100)
Other Types
6.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Approved
Clinical Trials
Pre-Clinical
6.4. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Human Immunodeficiency Virus (HIV)
Chronic Inflammatory Disease
Stem Cell Mobilization
Immune And Autoimmune Diseases
6.5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.6. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of BL-8040, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology Applications (Leukemia, Lymphoma)
Stem Cell Mobilization
6.7. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of GMI-1359, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Breast Cancer, Solid Tumors)
Bone Marrow Mobilization
6.8. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Plerixafor (AMD3100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hematopoietic Stem Cell Mobilization
Cancer Treatment (Multiple Myeloma)
HIV Treatment (HIV Reservoirs)
6.9. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Balixafortide (POL6326), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Solid Tumors, Breast Cancer)
6.10. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of USL311, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stem Cell Mobilization
Oncology Applications
6.11. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Burixafor (GPC-100), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer Treatment (Lymphoma, Solid Tumors)
Stem Cell Mobilization
6.12. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Experimental Or Preclinical CXCR4 Antagonists
Combination Therapies With CXCR4 Antagonists
7. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Regional And Country Analysis
7.1. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
9.1. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
9.2. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
10.1. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
11.1. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
11.2. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
12.1. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
13.1. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
14.1. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
14.2. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
15.1. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
15.2. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
16.1. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.2. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
22.1. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
23.1. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
23.2. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
24.1. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
24.2. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
26.1. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Overview
26.2. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
27.1. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market, Segmentation By Product Pipeline, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market
